Switch theme
Sign up to access all valuation multiples
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
1997
498
LTM Revenue $20.4M
LTM EBITDA -$580M
$3.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cytokinetics has a last 12-month revenue (LTM) of $20.4M and a last 12-month EBITDA of -$580M.
In the most recent fiscal year, Cytokinetics achieved revenue of $18.5M and an EBITDA of -$493M.
Cytokinetics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cytokinetics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $20.4M | XXX | $18.5M | XXX | XXX | XXX |
| Gross Profit | $19.7M | XXX | -$321M | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | -1737% | XXX | XXX | XXX |
| EBITDA | -$580M | XXX | -$493M | XXX | XXX | XXX |
| EBITDA Margin | -2843% | XXX | -2671% | XXX | XXX | XXX |
| EBIT | -$585M | XXX | -$536M | XXX | XXX | XXX |
| EBIT Margin | -2867% | XXX | -2903% | XXX | XXX | XXX |
| Net Profit | -$629M | XXX | -$590M | XXX | XXX | XXX |
| Net Margin | -3083% | XXX | -3191% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $562M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cytokinetics's stock price is $31.
Cytokinetics has current market cap of $3.7B, and EV of $3.6B.
See Cytokinetics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.6B | $3.7B | XXX | XXX | XXX | XXX | $-5.45 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cytokinetics has market cap of $3.7B and EV of $3.6B.
Cytokinetics's trades at 192.6x EV/Revenue multiple, and -7.2x EV/EBITDA.
Equity research analysts estimate Cytokinetics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cytokinetics has a P/E ratio of -5.9x.
See valuation multiples for Cytokinetics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.7B | XXX | $3.7B | XXX | XXX | XXX |
| EV (current) | $3.6B | XXX | $3.6B | XXX | XXX | XXX |
| EV/Revenue | 174.3x | XXX | 192.6x | XXX | XXX | XXX |
| EV/EBITDA | -6.1x | XXX | -7.2x | XXX | XXX | XXX |
| EV/EBIT | -6.1x | XXX | -6.6x | XXX | XXX | XXX |
| EV/Gross Profit | 180.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.9x | XXX | -6.3x | XXX | XXX | XXX |
| EV/FCF | -13.5x | XXX | -8.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCytokinetics's last 12 month revenue growth is 344%
Cytokinetics's revenue per employee in the last FY averaged $37K, while opex per employee averaged $0.4M for the same period.
Cytokinetics's rule of 40 is -5721% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cytokinetics's rule of X is -1983% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cytokinetics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 344% | XXX | 218% | XXX | XXX | XXX |
| EBITDA Margin | -2843% | XXX | -2671% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -5721% | XXX | -2327% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -1983% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $37K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1165% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cytokinetics acquired XXX companies to date.
Last acquisition by Cytokinetics was XXXXXXXX, XXXXX XXXXX XXXXXX . Cytokinetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cytokinetics founded? | Cytokinetics was founded in 1997. |
| Where is Cytokinetics headquartered? | Cytokinetics is headquartered in United States of America. |
| How many employees does Cytokinetics have? | As of today, Cytokinetics has 498 employees. |
| Who is the CEO of Cytokinetics? | Cytokinetics's CEO is Mr. Robert I. Blum. |
| Is Cytokinetics publicy listed? | Yes, Cytokinetics is a public company listed on NAS. |
| What is the stock symbol of Cytokinetics? | Cytokinetics trades under CYTK ticker. |
| When did Cytokinetics go public? | Cytokinetics went public in 2004. |
| Who are competitors of Cytokinetics? | Similar companies to Cytokinetics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cytokinetics? | Cytokinetics's current market cap is $3.7B |
| What is the current revenue of Cytokinetics? | Cytokinetics's last 12 months revenue is $20.4M. |
| What is the current revenue growth of Cytokinetics? | Cytokinetics revenue growth (NTM/LTM) is 344%. |
| What is the current EV/Revenue multiple of Cytokinetics? | Current revenue multiple of Cytokinetics is 174.3x. |
| Is Cytokinetics profitable? | Yes, Cytokinetics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cytokinetics? | Cytokinetics's last 12 months EBITDA is -$580M. |
| What is Cytokinetics's EBITDA margin? | Cytokinetics's last 12 months EBITDA margin is -2843%. |
| What is the current EV/EBITDA multiple of Cytokinetics? | Current EBITDA multiple of Cytokinetics is -6.1x. |
| What is the current FCF of Cytokinetics? | Cytokinetics's last 12 months FCF is -$263M. |
| What is Cytokinetics's FCF margin? | Cytokinetics's last 12 months FCF margin is -1288%. |
| What is the current EV/FCF multiple of Cytokinetics? | Current FCF multiple of Cytokinetics is -13.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
